Physician profile
Wiley D Bunn
NPI 1902982473
$200,820.85
in general payments reported to CMS, 2019-2025
20 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $15K · 2021: $27K · 2022: $26K · 2023: $7,723 · 2024: $59K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Travel and Lodging: $11K · Food and Beverage: $3,711 · Consulting Fee: $3,200 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,600.00 |
| Travel and Lodging | $11,050.68 |
| Food and Beverage | $3,711.00 |
| Consulting Fee | $3,200.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $118,719.83 | 2020-2025 | Jemperli, Zejula |
| Clovis Oncology, INC. | $32,082.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $26,316.22 | 2019-2025 | Lynparza |
| Tesaro, INC. | $19,572.27 | 2019 | |
| Medical Device Business Services, INC. | $1,405.72 | 2024 | |
| Abbvie INC. | $417.51 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $404.62 | 2020-2024 | Myrisk, Precisetumor |
| Genmab U.S., INC. | $348.18 | 2023-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $233.00 | 2019-2024 | |
| Immunogen, INC. | $225.67 | 2023 | Elahere |
| Eisai INC. | $213.83 | 2024-2025 | |
| Tela Bio, INC. | $210.00 | 2024 | Ovitex 2s |
| Amgen INC. | $132.47 | 2019 | |
| Intuitive Surgical, INC. | $120.31 | 2024 | |
| Lupin INC. | $101.88 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.99 | 2025 | |
| Therapeuticsmd, INC. | $96.80 | 2019 | |
| Kyowa Kirin, INC. | $84.46 | 2019 | |
| Hologic Sales and Service, LLC | $22.75 | 2019 | |
| Smith+Nephew, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wiley Bunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.